References
- CollignonJLousbergLSchroederHJerusalemGTriple-negative breast cancer: treatment challenges and solutionsBreast Cancer: Targets and Therapy2016893107
- LehmannBDBauerJAChenXIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest201112172750276721633166
- GucalpATolaneySIsakoffSJTranslational Breast Cancer Research Consortium (TBCRC 011)Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancerClin Cancer Res201319195505551223965901
- RicciardiGRAdamoBIeniAAndrogen receptor (AR), E-cad-herin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patientsPLoS One201536e012836826039245
- YuKDZhuRZhanMIdentification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancerClin Cancer Res201319102723273323549873
- AnestisAKaramouzisMVDalagiorgouGPapavassiliouAGIs androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?Cancer Treat Rev201541654755325944485